tetano
Editor, Senior Moderator
Biochem Biophys Res Commun. 2014 May 22. pii: S0006-291X(14)00932-2. doi: 10.1016/j.bbrc.2014.05.060. [Epub ahead of print]
Human monoclonal antibodies derived from a patient infected with 2009 pandemic influenza A virus broadly cross-neutralize group 1 influenza viruses.
Pan Y1, Sasaki T2, Kubota-Koketsu R3, Inoue Y2, Yasugi M4, Yamashita A1, Ramadhany R1, Arai Y1, Du A2, Boonsathorn N5, Ibrahim MS6, Daidoji T7, Nakaya T8, Ono KI9, Okuno Y10, Ikuta K11, Watanabe Y12.
Author information
Abstract
Influenza viruses are a continuous threat to human public health because of their ability to evolve rapidly through genetic drift and reassortment. Three human monoclonal antibodies (HuMAbs) were generated in this study, 1H11, 2H5 and 5G2, and they cross-neutralize a diverse range of group 1 influenza A viruses, including seasonal H1N1, 2009 pandemic H1N1 (H1N1pdm) and avian H5N1 and H9N2. The three HuMAbs were prepared by fusing peripheral blood lymphocytes from an H1N1pdm-infected patient with a newly developed fusion partner cell line, SPYMEG. All the HuMAbs had little hemagglutination inhibition activity but had strong membrane-fusion inhibition activity against influenza viruses. A protease digestion assay showed the HuMAbs targeted commonly a short α-helix region in the stalk of the hemagglutinin. Furthermore, Ile45Phe and Glu47Gly double substitutions in the α-helix region made the HA unrecognizable by the HuMAbs. These two amino acid residues are highly conserved in the HAs of H1N1, H5N1 and H9N2 viruses. The HuMAbs reported here may be potential candidates for the development of therapeutic antibodies against group 1 influenza viruses.
Copyright ? 2014. Published by Elsevier Inc.
KEYWORDS:
Cross-neutralizing antibody, Global epitope, Human monoclonal antibody, Influenza A virus
PMID:
24858683
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24858683
Human monoclonal antibodies derived from a patient infected with 2009 pandemic influenza A virus broadly cross-neutralize group 1 influenza viruses.
Pan Y1, Sasaki T2, Kubota-Koketsu R3, Inoue Y2, Yasugi M4, Yamashita A1, Ramadhany R1, Arai Y1, Du A2, Boonsathorn N5, Ibrahim MS6, Daidoji T7, Nakaya T8, Ono KI9, Okuno Y10, Ikuta K11, Watanabe Y12.
Author information
Abstract
Influenza viruses are a continuous threat to human public health because of their ability to evolve rapidly through genetic drift and reassortment. Three human monoclonal antibodies (HuMAbs) were generated in this study, 1H11, 2H5 and 5G2, and they cross-neutralize a diverse range of group 1 influenza A viruses, including seasonal H1N1, 2009 pandemic H1N1 (H1N1pdm) and avian H5N1 and H9N2. The three HuMAbs were prepared by fusing peripheral blood lymphocytes from an H1N1pdm-infected patient with a newly developed fusion partner cell line, SPYMEG. All the HuMAbs had little hemagglutination inhibition activity but had strong membrane-fusion inhibition activity against influenza viruses. A protease digestion assay showed the HuMAbs targeted commonly a short α-helix region in the stalk of the hemagglutinin. Furthermore, Ile45Phe and Glu47Gly double substitutions in the α-helix region made the HA unrecognizable by the HuMAbs. These two amino acid residues are highly conserved in the HAs of H1N1, H5N1 and H9N2 viruses. The HuMAbs reported here may be potential candidates for the development of therapeutic antibodies against group 1 influenza viruses.
Copyright ? 2014. Published by Elsevier Inc.
KEYWORDS:
Cross-neutralizing antibody, Global epitope, Human monoclonal antibody, Influenza A virus
PMID:
24858683
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24858683